Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega.
This study assesses viremia, provirus and blood cytokine profile in naturally FIV-infected cats treated with two distinct protocols of interferon omega (rFeIFN-ω). Samples from FIV-cats previously submitted to two single-arm studies were used: 7/18 received the licensed/subcutaneous protocol (SC) while 11/18 were treated orally (PO). Viremia, provirus and blood mRNA expression of interleukin (IL)-1, IL-4, IL-6, IL-10, IL-12p40, Interferon-γ and Tumor Necrosis Factor-α were monitored by Real-Time qPCR. Concurrent plasma levels of IL-6, IL-12p40 and IL-4 were assessed by ELISA. IL-6 plasma levels decreased in the SC group (p = 0.031). IL-6 mRNA expression (p = 0.037) decreased in the PO group, albeit not sufficiently to change concurrent plasma levels. Neither viremia nor other measured cytokines changed with therapy. Proviral load increased in the SC group (p = 0.031), which can be justified by a clinically irrelevant increase of lymphocyte count. Independently of the protocol, rFeIFN-ω seems to act on innate immunity by reducing pro-inflammatory stimulus.
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300-477 Lisbon, Portugal; Centre Hospitalier Vétérinaire Fregis, 43 Av. Aristide Briand, 94110 Arcueil, France.
Rodolfo O
RO
Leal
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300-477 Lisbon, Portugal. Electronic address: solange@fmv.ulisboa.pt.
Solange
S
Gil
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300-477 Lisbon, Portugal.
Ana
A
Duarte
Virbac, 13e rue LID - BP 27, F 06511 Carros, France.
David
D
McGahie
London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; Centro de Estatística e Aplicações da Universidade de Lisboa, FCUL, Bloco C6-Piso 4 Campo Grande, 1749-016 Lisboa, Portugal.
Nuno
N
Sepúlveda
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300-477 Lisbon, Portugal.
Maria M R E
MM
Niza
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300-477 Lisbon, Portugal.
Luís
L
Tavares
D000284:Administration, Oral; D000818:Animals; D002371:Cat Diseases / Q000097:blood / Q000276:immunology / Q000821:virology*; D002415:Cats / Q000821:virology*; D016207:Cytokines / Q000097:blood*; D016181:Feline Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000276:immunology; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D053762:Interleukin-12 Subunit p40 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D012333:RNA, Messenger / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects / Q000276:immunology; D014766:Viremia / Q000097:blood / Q000276:immunology / Q000662:veterinary*
D016207:Cytokines; D007155:Immunologic Factors; D007370:Interferon Type I; D053762:Interleukin-12 Subunit p40; D015850:Interleukin-6; D012333:RNA, Messenger; D011994:Recombinant Proteins; C063743:interferon omega 1; D015847:Interleukin-4
Cytokine; FIV; Feline; Immunomodulator; Interferon